Yan Kong

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring <i>c-Kit</i> Mutation or Amplification

Jun Guo, Lu Si, Yan Kong et al. · Journal of Clinical Oncology · 2011 · 673 citations · Full text

Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets

Felicity Newell, Yan Kong, James S. Wilmott et al. · Nature Communications · 2019 · 319 citations · Full text

Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Bin Lian, Lu Si, Chuanliang Cui et al. · Clinical Cancer Research · 2013 · 193 citations

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients

Bixia Tang, Xieqiao Yan, Xinan Sheng et al. · Journal of Hematology & Oncology · 2019 · 185 citations · Full text

Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients

Jiayi Yu, Xiaowen Wu, Junya Yan et al. · Journal of Hematology & Oncology · 2018 · 183 citations · Full text